Theresa Sakyiama, MD
Child & Adolescent Psychiatry · Wheaton, ILNPI 1376586800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $911 and has fallen 83.9% since, to $147 in 2025.
Across 104 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$467
- Corium, LLC$334
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$222
- Takeda Pharmaceuticals U.S.A., Inc.$204
- AbbVie$187
- Ironshore Pharmaceuticals Inc.$151
- plus $944 from 19 others
What the payments were for
- Food & beverage$2,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$357
How this compares
$2,510 in reported general payments places this provider in the 85th percentile of 124 child & adolescent psychiatry providers in Illinois.
See all child & adolescent psychiatry providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 18 | $519 |
| Sertraline Hcl | 13 | $220 |
| Mirtazapine | 14 | $139 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $138 |
| Fluoxetine Hcl | 19 | $135 |
| Buspirone Hcl | 11 | $72 |
| Lamotrigine | 11 | $67 |
| Trazodone Hcl | 20 | $66 |
| Aripiprazole | 12 | $65 |
| Zolpidem Tartrate | 22 | $48 |
| Clonazepam | 15 | $34 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Wheaton
- Amna SiddiqueWheaton$2K
- Fareha MalikElgin$57K
- Gregory TeasHoffman Estates$36K
- Martins AdeoyeOrland Park$10K
- Daniel MartinezLombard$8K
- Khalid ArshadKankakee$8K
- Talat GhausHinsdale$6K
- Walter PedemonteOak Park$5K
- Shazia TayyabLibertyville$5K
- Bradley PechterMelrose Park$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.